logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 9856321 B1

PDFFull Text
Date of Patent:
Jan. 02, 2018

Filed:

Sep. 04, 2015

Anti-dr5 antibodies, polynucleotides and methods

Applicant:

Daiichi Sankyo Company, Limited, Chuo-ku, Tokyo, JP;

Inventors:

Toshiaki Ohtsuka, Saitama, JP;

Takeshi Takizawa, Tokyo, JP;

Akiko Oguni, Tokyo, JP;

Tatsuji Matsuoka, Tokyo, JP;

Hiroko Yoshida, Tokyo, JP;

Yumi Matsui, Tokyo, JP;

Assignee:

Daiichi Sankyo Company, Limited, Chuo-ku, Tokyo, JP;

Attorney:

Christensen O'Connor Johnson Kindness PLLC

Primary Examiner:

Claire Kaufman

Int. Cl.
CPC ...
C12P 21/08 (2006.01); C07K 16/28 (2006.01); A61K 39/395 (2006.01); C07K 14/705 (2006.01); A61K 31/337 (2006.01); A61K 31/4745 (2006.01); A61K 31/475 (2006.01); A61K 31/555 (2006.01); A61K 31/439 (2006.01); A61K 31/4545 (2006.01); A61K 31/513 (2006.01); C07K 16/30 (2006.01); A61K 45/06 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2878 (2013.01); A61K 31/337 (2013.01); A61K 31/439 (2013.01); A61K 31/4545 (2013.01); A61K 31/475 (2013.01); A61K 31/4745 (2013.01); A61K 31/513 (2013.01); A61K 31/555 (2013.01); A61K 39/3955 (2013.01); A61K 39/39558 (2013.01); A61K 45/06 (2013.01); C07K 14/70578 (2013.01); C07K 16/30 (2013.01); A61K 2039/505 (2013.01); C07K 2299/00 (2013.01); C07K 2317/24 (2013.01); C07K 2317/34 (2013.01); C07K 2317/51 (2013.01); C07K 2317/515 (2013.01); C07K 2317/55 (2013.01); C07K 2317/73 (2013.01); C07K 2317/92 (2013.01); C07K 2319/30 (2013.01);
Abstract

The present invention relates to an antibody which has a therapeutic effect on cancer, an autoimmune disease, or an inflammatory disease. That is, the present invention relates to an antibody which exhibits a cytotoxic activity against death domain-containing receptor-expressing cells through apoptosis. [Object] An object of the invention is to provide a pharmaceutical having a therapeutic effect on cancer. [Means for Resolution] A novel anti-DR5 antibody capable of inducing apoptosis in cells has more potent cytotoxic activity than currently available anti-DR5 antibodies.

Find Patent Forward Citations

Loading…